Application note

Rapidly assess CAR T cell strategies

Rapid assessment of CAR T-cell strategies for multiple myeloma with the z-Movi® Cell Avidity Analyzer

In this application note, we highlight cell avidity and in vivo experiments performed in collaboration with the team of Dr. Eric Smith (DanaFarber Cancer Institute) and Prof. Carlos de Larrea (Hospital Clínic Barcelona) and show how one can use the z-Movi to:

  • Rapidly identify new, effective CAR T-cell therapy candidates for multiple myeloma through cell avidity measurements.
  • Predict in vivo outcomes by comparing cell avidity outcomes between CAR T-cell populations.
  •  Retrieve high-throughput data from different CAR T-cell populations within 24 hours.

Download a copy of the application note here on the right to discover how you can perform cell avidity analysis assessment to explore and validate CAR T-cell functionality and obtain predictive, reproducible, and rapid results at the single-cell level without compromising cell viability.

Download the application note today:

By agreeing to receive marketing communications, you subscribe to our newsletter. You can change your mind at any time by clicking the unsubscribe link in any marketing email you receive from us. By submitting the form you agree to LUMICKS' privacy policy.

z-Movi®

Cell Avidity Analyzer

The z-Movi® is a unique instrument that measures the avidity between immune cells and their targets, enabling you to identify the most potent immunotherapeutic effector cells. This new technology provides you with predictive, reproducible, and fast high-throughput results at a single-cell resolution without compromising cell viability. All within a compact little box that easily fits inside the flow hood for sterile and safe sample handling.

Curious to learn more?